原细小病毒属病毒感染及其抗肿瘤机制研究进展

doi:10.11843/j.issn.0366-6964.2023.11.011

摘要/Abstract

摘要： 原细小病毒(Protoparvovirus,PtPV)是一类感染多种动物或人类并引起广泛的病理反应的病毒。在PtPV感染过程中,其衣壳蛋白和非结构蛋白发挥了重要作用。衣壳蛋白通过与宿主细胞膜上的受体相互作用,促使PtPV进入宿主细胞。非结构蛋白则在宿主细胞内复制时发挥作用。PtPV的非结构蛋白NS1是一种关键蛋白,它不仅在病毒复制中发挥作用,还具有嗜瘤性和溶瘤性。研究表明,NS1蛋白可以抑制细胞增殖并诱导细胞凋亡,这使得异位表达NS1蛋白成为潜在的抗肿瘤策略。PtPV的衣壳蛋白也具有广泛的应用前景,衣壳蛋白可作为载体,在基因疗法和药物递送应用中发挥重要作用:衣壳蛋白组装为病毒颗粒,装载外源基因或药物,并通过PtPV的感染途径将其输送到宿主细胞中。这种基于病毒的基因或药物递送系统已被广泛研究,并在临床治疗中应用。虽然已了解PtPV感染的关键因素和效应,但其分子机制尚不完全清楚。研究表明,PtPV可能涉及多个信号通路的调节和活化,包括炎症反应、DNA损伤应答和细胞凋亡等。尽管PtPV可能引起多种疾病,但随着研究的深入,目前已有相关药物和疫苗可用于预防或治疗PtPV感染,而其衣壳蛋白和非结构蛋白在生物技术和医学领域具有重要的应用前景。关于PtPV的进一步研究和深入理解会促使其应用于新的领域,并更好地应对与其感染及相关疾病相关的挑战。

关键词: 细小病毒, 原细小病毒属, 感染, 抗肿瘤, 机制

Abstract: Protoparvovirus (PtPV) is a type of virus that infects various animals or humans and causes a wide range of pathological reactions. During PtPV infection,its capsid protein and non-structural protein play important roles. The capsid protein interacts with receptors on the host cell membrane,allowing PtPV to enter the host cell. Non-structural proteins,on the other hand,play a role in replication within the host cell. PtPV’s non-structural protein NS1 is a key protein that not only plays a role in virus replication but also has oncolytic and lytic properties. Studies have shown that NS1 protein can inhibit cell proliferation and induce cell apoptosis,making ectopic expression of NS1 protein a potential anti-tumor strategy. PtPV’s capsid protein also has a wide range of potential applications as a carrier in gene therapy and drug delivery: the capsid protein assembles into virus-like particles that can load foreign genes or drugs and deliver them to host cells through PtPV’s infection pathway. This virus-based gene or drug delivery system has been widely studied and applied in clinical treatment. Although the key factors and effects of PtPV infection are understood,its molecular mechanisms are not fully understood. Studies have shown that PtPV may involve the regulation and activation of multiple signaling pathways,including inflammatory responses,DNA damage responses,and cell apoptosis. Although PtPV may cause a variety of diseases,there are currently drugs and vaccines available to prevent or treat PtPV infection,and its capsid protein and non-structural protein have important applications in biotechnology and medicine. In the future,through further research and understanding of PtPV,it may be possible to apply it to new fields and better address the challenges of its infection and related diseases.

Key words: parvovirus, Protoparvovirus, infection, antineoplastic, mechanism

中图分类号:

商金源, 闫曼平, 叶京飞, 程悦宁, 王振军, 冯二凯, 王春霞, 赵艳, 朱先鹏, 廖远军, 罗国良. 原细小病毒属病毒感染及其抗肿瘤机制研究进展[J]. 畜牧兽医学报, 2023, 54(11): 4551-4559.

SHANG Jinyuan, YAN Manping, YE Jingfei, CHENG Yuening, WANG Zhenjun, FENG Erkai, WANG Chunxia, ZHAO Yan, ZHU Xianpeng, LIAO Yuanjun, LUO Guoliang. Research Progress on Virus Infection and Its Anti-tumor Mechanisms of Protoparvovirus[J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(11): 4551-4559.

参考文献 51

[1]	GIL-RANEDO J, HERNANDO E, RIOLOBOS L, et al. The mammalian cell cycle regulates parvovirus nuclear capsid assembly[J]. PLoS Pathog, 2015, 11(6):e1004920.
[2]	ROS C, BAYAT N, WOLFISBERG R, et al. Protoparvovirus cell entry[J]. Viruses, 2017, 9(11):313.
[3]	XIA C F, DONG X S, LI H, et al. Cancer statistics in China and united states, 2022:profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590.
[4]	PAN C X, KIM D Y, NAMBUDIRI V E. Novel cancer treatment using oncolytic virus therapy[M]//REZAEI N. Handbook of Cancer and Immunology. Cham:Springer, 2022:1-43.
[5]	MIETZSCH M, PÉNZES J J, AGBANDJE-MCKENNA M. Twenty-five years of structural parvovirology[J]. Viruses, 2019, 11(4):362.
[6]	MATTOLA S, SALOKAS K, AHO V, et al. Parvovirus nonstructural protein 2 interacts with chromatin-regulating cellular proteins[J]. PLoS Pathog, 2022, 18(4):e1010353.
[7]	LEZHNIN Y N, KRAVCHENKO Y E, FROLOVA E I, et al. Oncotoxic proteins in cancer therapy:mechanisms of action[J]. Mol Biol (Mosk), 2015, 49(2):231-243.
[8]	MÄNTYLÄ E, KANN M, VIHINEN-RANTA M. Protoparvovirus knocking at the nuclear door[J]. Viruses, 2017, 9(10):286.
[9]	MATTOLA S, HAKANEN S, SALMINEN S, et al. Concepts to reveal parvovirus-nucleus interactions[J]. Viruses, 2021, 13(7):1306.
[10]	KANG H T, LIU D F, TIAN J, et al. Feline Panleucopenia virus NS2 suppresses the host IFN-β induction by disrupting the interaction between TBK1 and STING[J]. Viruses, 2017, 9(1):23.
[11]	MÉSZÁROS I, TÓTH R, OLASZ F, et al. The SAT protein of porcine parvovirus accelerates viral spreading through induction of irreversible endoplasmic reticulum stress[J]. J Virol, 2017, 91(16):e00627-17.
[12]	FARR G A, COTMORE S F, TATTERSALL P. VP2 cleavage and the leucine ring at the base of the fivefold cylinder control PH-dependent externalization of both the VP1 N terminus and the genome of minute virus of mice[J]. J Virol, 2006, 80(1):161-171.
[13]	VIHINEN-RANTA M, WANG D, WEICHERT W S, et al. The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection[J]. J Virol, 2002, 76(4):1884-1891.
[14]	TU M Y, LIU F, CHEN S, et al. Role of capsid proteins in parvoviruses infection[J]. Virol J, 2015, 12:114.
[15]	FEI-FEI D, YONG-FENG Z, JIAN-LI W, et al. Molecular characterization of feline panleukopenia virus isolated from mink and its pathogenesis in mink[J]. Vet Microbiol, 2017, 205:92-98.
[16]	COTMORE S F, AGBANDJE-MCKENNA M, CANUTI M, et al. ICTV virus taxonomy profile:Parvoviridae[J]. J Gen Virol, 2019, 100(3):367-368.
[17]	PÉNZES J J, SÖDERLUND-VENERMO M, CANUTI M, et al. Reorganizing the family Parvoviridae:a revised taxonomy independent of the canonical approach based on host association[J]. Arch Virol, 2020, 165(9):2133-2146.
[18]	PARKER J S L, MURPHY W J, WANG D, et al. Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells[J]. J Virol, 2001, 75(8):3896-3902.
[19]	SIMPSON A A, CHANDRASEKAR V, HÉBERT B, et al. Host range and variability of calcium binding by surface loops in the capsids of canine and feline parvoviruses[J]. J Mol Biol, 2000, 300(3):597-610.
[20]	CURETON D K, HARBISON C E, COCUCCI E, et al. Limited transferrin receptor clustering allows rapid diffusion of canine parvovirus into clathrin endocytic structures[J]. J Virol, 2012, 86(9):5330-5340.
[21]	GARCIN P O, PANTÉ N. The minute virus of mice exploits different endocytic pathways for cellular uptake[J]. Virology, 2015, 482:157-166.
[22]	BOISVERT M, BOUCHARD-LÉVESQUE V, FERNANDES S, et al. Classic nuclear localization signals and a novel nuclear localization motif are required for nuclear transport of porcine parvovirus capsid proteins[J]. J Virol, 2014, 88(20):11748-11759.
[23]	MÄNTYLÄ E, AHO V, KANN M, et al. Cytoplasmic parvovirus capsids recruit importin beta for nuclear delivery[J]. J Virol, 2020, 94(4):e01532-19.
[24]	AU S, COHEN S, PANTÉ N. Microinjection of Xenopus laevis oocytes as a system for studying nuclear transport of viruses[J]. Methods, 2010, 51(1):114-120.
[25]	CHRISTENSEN J, TATTERSALL P. Parvovirus initiator protein NS1 and RPA coordinate replication fork progression in a reconstituted DNA replication system[J]. J Virol, 2002, 76(13):6518-6531.
[26]	COTMORE S F, TATTERSALL P. Parvovirus diversity and DNA damage responses[J]. Cold Spring Harb Perspect Biol, 2013, 5(2):a012989.
[27]	LYI S M, TAN M J A, PARRISH C R. Parvovirus particles and movement in the cellular cytoplasm and effects of the cytoskeleton[J]. Virology, 2014, 456-457:342-352.
[28]	MAROTO B, VALLE N, SAFFRICH R, et al. Nuclear export of the nonenveloped parvovirus virion is directed by an unordered protein signal exposed on the capsid surface[J]. J Virol, 2004, 78(19):10685-10694.
[29]	JINDAL H K, YONG C B, WILSON G M, et al. Mutations in the NTP-binding motif of minute virus of mice (MVM) NS-1 protein uncouple ATPase and DNA helicase functions[J]. J Biol Chem, 1994, 269(5):3283-3289.
[30]	NVESCH J P F, ROMMELAERE J. Tumor suppressing properties of rodent parvovirus NS1 proteins and their derivatives[M]//GRIMM S. Anticancer Genes. London:Springer, 2014:99-124.
[31]	MARCHINI A, BONIFATI S, SCOTT E M, et al. Oncolytic parvoviruses:from basic virology to clinical applications[J]. Virol J, 2015, 12(1):6.
[32]	GUPTA S K, YADAV P K, GANDHAM R K, et al. Canine parvovirus NS1 protein exhibits anti-tumor activity in a mouse mammary tumor model[J]. Virus Res, 2016, 213:289-298.
[33]	LIU P, CHEN S, WANG M S, et al. The role of nuclear localization signal in parvovirus life cycle[J]. Virol J, 2017, 14(1):80.
[34]	ARORA R, MALLA W A, TYAGI A, et al. Canine parvovirus and its non-structural gene 1 as oncolytic agents:mechanism of action and induction of anti-tumor immune response[J]. Front Oncol, 2021, 11:648873.
[35]	NVESCH J P F, LACROIX J, MARCHINI A, et al. Molecular pathways:rodent parvoviruses—mechanisms of oncolysis and prospects for clinical cancer treatment[J]. Clin Cancer Res, 2012, 18(13):3516-3523.
[36]	XU M, JIN X, ZHANG C, et al. TLR2-mediated NF-κB signaling pathway is involved in PPV1-induced apoptosis in PK-15 cells[J]. Vet Res Commun, 2023, 47(2):397-407.
[37]	JIN X H, YUAN Y X, ZHANG C, et al. Porcine parvovirus nonstructural protein NS1 activates NF-κB and it involves TLR2 signaling pathway[J]. J Vet Sci, 2020, 21(3):e50.
[38]	LI J W, BONIFATI S, HRISTOV G, et al. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas[J]. EMBO Mol Med, 2013, 5(10):1537-1555.
[39]	HAUSWIRTH P, GRABER P, BUCZAK K, et al. Design and characterization of mutated variants of the oncotoxic parvoviral protein NS1[J]. Viruses, 2023, 15(1):209.
[40]	ANGELOVA A, ROMMELAERE J. Immune system stimulation by oncolytic rodent protoparvoviruses[J]. Viruses, 2019, 11(5):415.
[41]	RAIMONDI C, FALASCA M. Targeting PDK1 in cancer[J]. Curr Med Chem, 2011, 18(18):2763-2769.
[42]	GELETNEKY K, HAJDA J, ANGELOVA A L, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial[J]. Mol Ther, 2017, 25(12):2620-2634.
[43]	DI PIAZZA M, MADER C, GELETNEKY K, et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells[J]. J Virol, 2007, 81(8):4186-4198.
[44]	HAJDA J, LEHMANN M, KREBS O, et al. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer:ParvOryx02 protocol[J]. BMC Cancer, 2017, 17(1):576.
[45]	HAJDA J, LEUCHS B, ANGELOVA A L, et al. Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2021, 27(20):5546-5556.
[46]	LANG S I, GIESE N A, ROMMELAERE J, et al. Humoral immune responses against minute virus of mice vectors[J]. J Gene Med, 2006, 8(9):1141-1150.
[47]	ALLISON A B, KOHLER D J, ORTEGA A, et al. Host-specific parvovirus evolution in nature is recapitulated by in vitro adaptation to different carnivore species[J]. PLoS Pathog, 2014, 10(11):e1004475.
[48]	BATTILANI M, BALBONI A, GIUNTI M, et al. Co-infection with feline and canine parvovirus in a cat[J]. Vet Ital, 2013, 49(1):127-129.
[49]	WANG X W, CARRAI M, VAN BRUSSEL K, et al. Low intrahost and interhost genetic diversity of Carnivore Protoparvovirus 1 in domestic cats during a feline panleukopenia outbreak[J]. Viruses, 2022, 14(7):1412.
[50]	程宝钰, 李子荷, 崔燕蕾, 等. 猫细小病毒的遗传演化及分离毒株的致病性分析[J]. 畜牧兽医学报, 2022, 53(9): 3121-3131.CHENG B Y, LI Z H, CUI Y L, et al. Genetic evolution of feline parvovirus and pathogenicity of an isolated strains[J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(9): 3121-3131. (in Chinese)
[51]	WITZIGMANN D, GROSSEN P, QUINTAVALLE C, et al. Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma[J]. J Control Release, 2021, 334:138-152.